Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Streptococcus pneumoniae | 5 | 2019 | 827 | 2.05 | Why? |
| Pneumococcal Vaccines | 6 | 2019 | 571 | 2.05 | Why? |
| Heptavalent Pneumococcal Conjugate Vaccine | 3 | 2019 | 64 | 1.41 | Why? |
| Israel | 17 | 2021 | 2751 | 1.32 | Why? |
| Vaccines, Conjugate | 2 | 2019 | 328 | 1.27 | Why? |
| Staphylococcus aureus | 4 | 2018 | 844 | 1.25 | Why? |
| Pneumococcal Infections | 4 | 2019 | 562 | 1.13 | Why? |
| Staphylococcal Infections | 4 | 2018 | 1099 | 1.02 | Why? |
| Carrier State | 4 | 2019 | 2100 | 1.02 | Why? |
| Serratia Infections | 1 | 2018 | 12 | 0.77 | Why? |
| Serratia marcescens | 1 | 2018 | 38 | 0.75 | Why? |
| Meningitis, Pneumococcal | 1 | 2018 | 35 | 0.74 | Why? |
| Serogroup | 2 | 2019 | 510 | 0.65 | Why? |
| Pneumonia, Pneumococcal | 1 | 2018 | 251 | 0.59 | Why? |
| Air Travel | 1 | 2020 | 585 | 0.52 | Why? |
| Interleukin-17 | 1 | 2018 | 602 | 0.50 | Why? |
| Travel-Related Illness | 1 | 2020 | 1357 | 0.50 | Why? |
| Asymptomatic Diseases | 2 | 2021 | 3444 | 0.44 | Why? |
| Immunity, Herd | 2 | 2021 | 1011 | 0.41 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 2 | 2018 | 711 | 0.39 | Why? |
| Equipment Contamination | 1 | 2018 | 1308 | 0.39 | Why? |
| Community-Acquired Infections | 3 | 2019 | 2328 | 0.37 | Why? |
| Health Personnel | 5 | 2021 | 29646 | 0.35 | Why? |
| Waste Water | 1 | 2018 | 2185 | 0.34 | Why? |
| Vaccination | 8 | 2021 | 19050 | 0.33 | Why? |
| Methicillin Resistance | 2 | 2018 | 77 | 0.30 | Why? |
| Schools | 1 | 2020 | 4187 | 0.28 | Why? |
| Nasopharynx | 2 | 2019 | 10224 | 0.25 | Why? |
| Cross Infection | 3 | 2019 | 8675 | 0.23 | Why? |
| Adverse Outcome Pathways | 1 | 2021 | 63 | 0.22 | Why? |
| Electrophoresis, Gel, Pulsed-Field | 1 | 2018 | 78 | 0.19 | Why? |
| Umbilicus | 1 | 2017 | 12 | 0.18 | Why? |
| Masks | 1 | 2020 | 8528 | 0.18 | Why? |
| Ear | 1 | 2017 | 51 | 0.17 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.17 | Why? |
| Female | 20 | 2021 | 380317 | 0.16 | Why? |
| Hospitals, Special | 1 | 2021 | 523 | 0.16 | Why? |
| Male | 18 | 2021 | 367725 | 0.15 | Why? |
| Odds Ratio | 2 | 2018 | 5861 | 0.15 | Why? |
| Meningitis, Bacterial | 1 | 2017 | 111 | 0.15 | Why? |
| Treatment Failure | 1 | 2021 | 2106 | 0.14 | Why? |
| Adult | 14 | 2021 | 244371 | 0.14 | Why? |
| Infant | 6 | 2021 | 30274 | 0.14 | Why? |
| Prevalence | 4 | 2021 | 25773 | 0.13 | Why? |
| Rectum | 1 | 2017 | 495 | 0.13 | Why? |
| Species Specificity | 1 | 2018 | 1356 | 0.13 | Why? |
| Middle Aged | 13 | 2021 | 270681 | 0.12 | Why? |
| Th17 Cells | 1 | 2018 | 657 | 0.12 | Why? |
| Milk, Human | 1 | 2021 | 956 | 0.12 | Why? |
| Ships | 1 | 2020 | 1046 | 0.12 | Why? |
| Interleukins | 1 | 2018 | 762 | 0.12 | Why? |
| Methicillin | 1 | 2011 | 73 | 0.11 | Why? |
| Intensive Care Units | 1 | 2018 | 29594 | 0.11 | Why? |
| Anaphylaxis | 1 | 2021 | 940 | 0.11 | Why? |
| Humans | 26 | 2021 | 930598 | 0.11 | Why? |
| Nose | 1 | 2017 | 1093 | 0.11 | Why? |
| Interleukin-10 | 1 | 2018 | 1409 | 0.11 | Why? |
| History, 21st Century | 1 | 2018 | 1849 | 0.11 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 1261 | 0.11 | Why? |
| Medical Staff, Hospital | 1 | 2021 | 1258 | 0.10 | Why? |
| Mass Vaccination | 1 | 2021 | 1101 | 0.10 | Why? |
| Nasal Mucosa | 1 | 2018 | 1218 | 0.10 | Why? |
| Disease Reservoirs | 1 | 2018 | 1672 | 0.09 | Why? |
| Antibodies, Viral | 4 | 2021 | 51949 | 0.09 | Why? |
| Leukocytes, Mononuclear | 1 | 2018 | 2115 | 0.09 | Why? |
| Infection Control | 4 | 2021 | 23131 | 0.09 | Why? |
| Aged | 9 | 2021 | 215776 | 0.09 | Why? |
| Young Adult | 7 | 2021 | 93724 | 0.08 | Why? |
| Protein Domains | 1 | 2020 | 6563 | 0.08 | Why? |
| Child, Preschool | 4 | 2021 | 36283 | 0.08 | Why? |
| Drug Resistance, Microbial | 1 | 2011 | 419 | 0.08 | Why? |
| Child | 4 | 2021 | 70012 | 0.08 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.08 | Why? |
| Parents | 1 | 2020 | 2758 | 0.08 | Why? |
| Mothers | 1 | 2017 | 1624 | 0.08 | Why? |
| Diagnosis, Differential | 1 | 2021 | 7220 | 0.08 | Why? |
| Tertiary Care Centers | 2 | 2020 | 8248 | 0.08 | Why? |
| Emergency Service, Hospital | 2 | 2021 | 14232 | 0.07 | Why? |
| International Cooperation | 1 | 2018 | 3436 | 0.07 | Why? |
| Triage | 2 | 2021 | 7151 | 0.07 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2021 | 13720 | 0.07 | Why? |
| Adolescent | 6 | 2021 | 86841 | 0.07 | Why? |
| Epidemiological Monitoring | 1 | 2017 | 3493 | 0.07 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.06 | Why? |
| Infant, Newborn | 3 | 2021 | 23105 | 0.06 | Why? |
| Case-Control Studies | 1 | 2021 | 17671 | 0.06 | Why? |
| Cross-Sectional Studies | 2 | 2020 | 53120 | 0.06 | Why? |
| Disease Outbreaks | 2 | 2021 | 27595 | 0.06 | Why? |
| Population Surveillance | 1 | 2018 | 4967 | 0.05 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.05 | Why? |
| Sepsis | 1 | 2017 | 3517 | 0.05 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.05 | Why? |
| Penicillin-Binding Proteins | 1 | 2018 | 31 | 0.05 | Why? |
| Lactation | 1 | 2021 | 361 | 0.05 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 9706 | 0.04 | Why? |
| Antibodies, Neutralizing | 2 | 2021 | 25288 | 0.04 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 7868 | 0.04 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.04 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.04 | Why? |
| DNA, Bacterial | 1 | 2018 | 835 | 0.03 | Why? |
| Middle East | 1 | 2018 | 1418 | 0.03 | Why? |
| Morbidity | 1 | 2019 | 1426 | 0.03 | Why? |
| Pregnancy Complications, Infectious | 1 | 2017 | 11559 | 0.03 | Why? |
| Workflow | 1 | 2021 | 2373 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.03 | Why? |
| Hypersensitivity | 1 | 2021 | 1137 | 0.03 | Why? |
| Residence Characteristics | 1 | 2021 | 1927 | 0.03 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2018 | 1115 | 0.03 | Why? |
| Diagnostic Tests, Routine | 1 | 2021 | 2643 | 0.02 | Why? |
| Drug Resistance, Bacterial | 1 | 2019 | 1414 | 0.02 | Why? |
| Bacterial Proteins | 1 | 2018 | 1318 | 0.02 | Why? |
| Microbial Sensitivity Tests | 1 | 2018 | 2886 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2020 | 3567 | 0.02 | Why? |
| Risk Factors | 1 | 2017 | 71621 | 0.02 | Why? |
| Anti-Bacterial Agents | 2 | 2019 | 10083 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.02 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
| Genomics | 1 | 2018 | 3118 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2021 | 6740 | 0.02 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2021 | 9893 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.02 | Why? |
| Public Health | 1 | 2011 | 16359 | 0.02 | Why? |
| Pandemics | 3 | 2021 | 389249 | 0.02 | Why? |
| Europe | 1 | 2021 | 12702 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.02 | Why? |
| Follow-Up Studies | 1 | 2021 | 17020 | 0.01 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2020 | 22971 | 0.01 | Why? |
| Hospitals | 1 | 2019 | 11793 | 0.01 | Why? |
| Retrospective Studies | 2 | 2021 | 105322 | 0.01 | Why? |
| Time Factors | 1 | 2021 | 31397 | 0.01 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2021 | 15978 | 0.01 | Why? |
| Telemedicine | 1 | 2021 | 25032 | 0.01 | Why? |
| Hospitalization | 1 | 2019 | 54280 | 0.01 | Why? |
Regev-Yochay's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(136)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(115)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_